|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-5-3
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Intravenous injection is the standard administration route of bortezomib; however, subcutaneous administration is an important alternative. We compared the efficacy and safety of subcutaneous versus intravenous bortezomib at the approved 1·3 mg/m(2) dose and twice per week schedule in patients with relapsed multiple myeloma.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1474-5488
|
|
pubmed:author |
pubmed-author:ArnulfBertrandB,
pubmed-author:CavetJamesJ,
pubmed-author:DeraedtWilliamW,
pubmed-author:EsseltineDixie-LeeDL,
pubmed-author:FengHuaibaoH,
pubmed-author:GirgisSuzetteS,
pubmed-author:GrishuninaMariaM,
pubmed-author:GrosickiSebastianS,
pubmed-author:HarousseauJean-LucJL,
pubmed-author:KaramaneshtIevgeniiI,
pubmed-author:KropffMartinM,
pubmed-author:LeleuXavierX,
pubmed-author:MasliakZvenyslavaZ,
pubmed-author:MoreauPhilippeP,
pubmed-author:PylypenkoHalynaH,
pubmed-author:RekhtmanGrigoriyG,
pubmed-author:RobakTadeuszT,
pubmed-author:ShubinaAnnaA,
pubmed-author:van de VeldeHelgiH
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
431-40
|
|
pubmed:dateRevised |
2011-8-16
|
|
pubmed:meshHeading |
pubmed-meshheading:21507715-Adult,
pubmed-meshheading:21507715-Aged,
pubmed-meshheading:21507715-Aged, 80 and over,
pubmed-meshheading:21507715-Antineoplastic Agents,
pubmed-meshheading:21507715-Asia,
pubmed-meshheading:21507715-Blood Cells,
pubmed-meshheading:21507715-Boronic Acids,
pubmed-meshheading:21507715-Disease-Free Survival,
pubmed-meshheading:21507715-Drug Administration Schedule,
pubmed-meshheading:21507715-Europe,
pubmed-meshheading:21507715-Humans,
pubmed-meshheading:21507715-Infusions, Intravenous,
pubmed-meshheading:21507715-Injections, Subcutaneous,
pubmed-meshheading:21507715-Kaplan-Meier Estimate,
pubmed-meshheading:21507715-Male,
pubmed-meshheading:21507715-Middle Aged,
pubmed-meshheading:21507715-Multiple Myeloma,
pubmed-meshheading:21507715-Neoplasm Staging,
pubmed-meshheading:21507715-Peripheral Nervous System Diseases,
pubmed-meshheading:21507715-Protease Inhibitors,
pubmed-meshheading:21507715-Pyrazines,
pubmed-meshheading:21507715-Recurrence,
pubmed-meshheading:21507715-South America,
pubmed-meshheading:21507715-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
|
|
pubmed:affiliation |
University Hospital, Nantes, France. philippe.moreau@chu-nantes.fr
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
